Annovis reported a FY 2025 net loss of USD 28.86 million, up 17% from the prior year. FY 2025 research and development expense rose 26% to USD 25.22 million, driven mainly by higher costs for patients in its Phase 3 Alzheimer’s trial and increased bioanalytical work. FY 2025 general and administrative expense fell 33% to USD 4.48 million, primarily due to lower stock-based compensation, stock listing and transfer fees, and corporate legal costs. FY 2025 interest income increased 111% to USD 0.7 million, reflecting higher cash and cash equivalents following a February 2025 public offering. Annovis ended FY 2025 with USD 19.5 million in cash and cash equivalents and said it expects this to fund operations into the third quarter of 2026, while noting it does not have sufficient capital to fund the next 12 months beyond the filing date.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-027751), on March 13, 2026, and is solely responsible for the information contained therein.
Comments